Investigating Claims Involving Geneius Biotechnology Inc.
The White Law Group is investigating potential securities claims involving broker dealers and financial advisors who may have unsuitably recommended Geneius Biotechnology Inc. to investors.
According to its website, Geneius Biotechnology, Inc. is focused on the development & commercialization of innovative autologous, adoptive T-cell therapies.
The company, based in Natick, MA, reportedly filed a form D to raise capital from investors in 2018. The total offering amount was purportedly $5,000,000.
Alternative investments such as this one, are generally speculative, high risk investments and due to these risks are often unsuitable for most investors. Despite?the risks of investing in alternative investments, brokerage firms continue to push this type of investment because of the high commissions associated with their sale and creation.
Brokerage firms have a responsibility to adequately disclose all risks before selling any investment and must consider suitability factors such as age, financial needs, and risk tolerance to name a few. Firms that do not perform adequate due diligences on an investment or demonstrate a breach of fiduciary duty can be held accountable for losses incurred through FINRA arbitration.
Free Consultation with a Securities Attorney
If you are concerned about an investment in Geneius Biotechnology Inc., the securities attorneys at The White Law Group may be able to help you by filing a complaint against your brokerage firm. Please call the offices at 888-637-5510 for a free consultation with a securities attorney.
The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois.
For more information on the firm, please visit https://www.whitesecuritieslaw.com.
Tags: Geneius Biotechnology Inc. complaints, Geneius Biotechnology Inc. investigation, Geneius Biotechnology Inc. investments, Geneius Biotechnology Inc. lawsuit, Geneius Biotechnology Inc. recovery options, Geneius Biotechnology Inc. review Last modified: December 9, 2022